NewsDesk World

Press releases and business news from around the world

Made possible by our supporters

Novartis Lifts Peak Sales Outlook for Three Key Drugs

Markets & Finance · ·

The drugmaker now sees $18 billion in combined peak sales, but its overall growth guidance is slightly softer and its shares fell.

Novartis Lifts Peak Sales Outlook for Three Key Drugs

Novartis now expects Kesimpta, Scemblix and Leqvio to reach $18 billion in combined peak sales, up from $14 billion. Investors still doubt that the company can keep growing after 2031, and its wider growth outlook is slightly more cautious.

A rough autumn in the pipeline

Novartis has had several clinical setbacks lately. Investors had been closely watching a September trial of pelacarsen, a cardiovascular drug, and it failed to show better outcomes. A day later, a late-stage study of del-desiran, aimed at a muscle-wasting disorder, also came up short. The stock fell almost 11%, its biggest single-day drop since 1987.

Novartis got del-desiran through a $12 billion deal for Avidity Biosciences earlier this year. After the failure, CEO Vas Narasimhan defended how the company allocates capital. Shareholders hold differing views on acquisitions, he said: some want more aggressive dealmaking, others another approach. He said he remains confident in the strategy and noted that total returns to shareholders have reached 275% in ten years, which he said puts Novartis among the sector's top performers.

Guidance runs to 2031

The company projects annual sales growth of 5% through 2031. Earlier guidance was 5% to 6% through 2030, so the new target is slightly less ambitious, though it spans a different five-year period.

The CEO linked the revised outlook to generic rivals to Kisqali, a breast cancer drug, which he expects on the US market in the second half of 2031.

Citi analysts said the 2031 sales guidance sits about 3% above consensus. They expect doubts about growth after 2031 to persist until further pipeline data arrives.

What lifted the three forecasts

Kesimpta treats multiple sclerosis, Scemblix treats leukaemia and Leqvio is a cholesterol medicine. Narasimhan said the upgrades were driven mainly by sales performance. Market share is growing for Kesimpta and Scemblix, he said, and demand for Leqvio is robust in the US and Asia.

"It's really that in-market commercial performance that's driving these upgrades," he told reporters on Thursday.

Shares fell 2.4% in mid-morning trading in Switzerland, even with the stronger forecasts for the three drugs.

Source: CNBC